Lecaneumab is a monoclonal antibody therapy designed to target and clear amyloid-beta plaques in the brain. It is used to slow cognitive decline in early-stage Alzheimer’s disease. Patients with mild symptoms or confirmed amyloid pathology benefit most, as treatment aims to preserve memory and function longer.
Get alerts when this topic surges in newsletters. Free to start.
Sign up freeExplore more trends:Trending Topics ·AI Trends ·Business Trends ·Finance Trends ·Technology Trends